How Atrial fibrillation Works

In a healthy heart, electrical signals begin at a single pacemaker called the sinoatrial node, then travel in an orderly wave across both atria before passing through a checkpoint to the ventricles. In atrial fibrillation, cells outside this natural pacemaker start firing on their own, creating multiple competing electrical sources. These abnormal signals don't simply travel in one direction—they curl back on themselves, forming spiral waves called "rotors" that spin continuously like electrical whirlpools across the atrial tissue.

These rotors can persist for hours or days, with electrical impulses radiating outward at rates of 300-600 cycles per minute. The atrial muscle cells try to respond to every signal that hits them, but they receive so many conflicting commands in such rapid succession that they can't coordinate a proper contraction. Instead of the atria squeezing in unison like a fist closing, individual muscle fibers twitch randomly and independently—the fibrillation that gives the condition its name.

What makes these electrical spirals particularly stubborn is that they're self-perpetuating. Each rotor creates a refractory wake of tissue that just fired and can't immediately fire again, which channels the signal into a curved path that loops back to where it started. By the time the wave completes its circuit, the tissue has recovered and is ready to fire again, keeping the spiral spinning indefinitely.

The atria's job is to add a final push of blood into the ventricles during each heartbeat—this "atrial kick" normally contributes about 20-30% of the heart's total output. When the atria fibrillate instead of contracting, they lose this pumping function entirely. The rapidly twitching muscle fibers generate no coordinated pressure, so blood simply sits in the atrial chambers rather than being actively squeezed downward.

The left atrial appendage, a small pouch-like structure extending from the left atrium, becomes especially problematic. This narrow, finger-shaped cavity has particularly sluggish flow even in healthy hearts, but it depends on strong atrial contractions to flush blood through. Without those contractions, blood in the appendage barely moves at all, creating a stagnant reservoir where flow velocity can drop to less than 20 centimeters per second—slow enough that red blood cells begin settling like sediment.

This pooling isn't just about volume—it fundamentally changes the blood's behavior. Normally, brisk flow keeps blood cells separated and tumbling past each other, but in stagnant conditions they drift into prolonged contact. The delicate balance between fluidity and clotting, which depends on constant motion to prevent inappropriate activation, begins to shift toward coagulation.

When blood flow slows dramatically in the fibrillating atria, the first responders are platelets—small cell fragments that constantly patrol for injury sites. In stagnant blood, platelets begin sticking to the atrial wall and to each other, forming small clumps. These aggregates release chemical signals like thromboxane and ADP that recruit more platelets, creating a growing network.

Simultaneously, the sluggish flow activates the coagulation cascade, a series of protein reactions that culminates in converting fibrinogen (a dissolved protein) into fibrin (long, sticky strands). These fibrin threads weave through the platelet clusters like rebar through concrete, creating a mesh that traps red blood cells and solidifies into a structured clot. In the left atrial appendage, where flow is slowest, these clots can grow to several centimeters across over days or weeks.

The real danger emerges when normal heart rhythm suddenly returns or when a piece of clot breaks loose. A fragment that detaches from the atrial wall becomes an embolus—a traveling clot carried through the left ventricle and out into the body's arterial system. Because about 90% of these clots form in the left atrium, and because the left side pumps oxygenated blood to the body, they most commonly travel to the brain. When a clot blocks a cerebral artery, it cuts off oxygen to brain tissue, causing a stroke—the most feared complication of atrial fibrillation.

The constant bombardment of electrical signals in atrial fibrillation forces atrial muscle cells to work far harder than they were designed for. Trying to respond to 300-600 signals per minute (versus the normal 60-100) is like forcing an engine to redline continuously. Over weeks and months, the atrial chambers dilate and stretch, with the muscle walls thinning as they expand like an over-inflated balloon.

This mechanical stress triggers a cellular remodeling process. Stretched heart muscle cells increase their production of fibroblasts—cells that normally repair injuries by laying down collagen. In AFib, these fibroblasts go into overdrive, depositing excess collagen between muscle fibers even without any injury. The result is fibrosis: patches of stiff, non-contractile scar tissue that replace functional muscle.

Electrical remodeling occurs simultaneously at the molecular level. Ion channels—the protein gates that control electrical signals in each cell—change their expression patterns in response to rapid firing. Potassium channels become more active while calcium channels become less so, shortening the refractory period (the recovery time after each heartbeat). This makes it even easier for rapid, chaotic signals to propagate, which is why atrial fibrillation tends to become more persistent over time.

This remodeling creates a vicious cycle summarized by the phrase "AFib begets AFib." The structural and electrical changes that result from fibrillation make the heart more susceptible to future episodes, which cause further remodeling. Without intervention, paroxysmal AFib (episodes that come and go) often progresses to persistent AFib (lasting more than seven days) and eventually to permanent AFib.

Antiarrhythmic medications work by targeting the specific ion channels that generate and propagate electrical signals in heart cells. Sodium channel blockers like flecainide slow the rapid upstroke of each electrical impulse, making it harder for signals to propagate quickly through atrial tissue—essentially applying brakes to runaway electrical activity. Potassium channel blockers like amiodarone extend the refractory period, forcing cells to wait longer before they can fire again, which disrupts the rapid cycling that sustains rotors.

Beta-blockers and calcium channel blockers take a different approach by targeting the atrioventricular (AV) node—the electrical gateway between atria and ventricles. While they don't stop the chaotic atrial activity, they prevent too many of those disorganized signals from reaching the ventricles. This rate control strategy keeps the ventricles beating at a reasonable 60-100 times per minute even while the atria fibrillate above, preventing the racing heartbeat that makes AFib symptomatic.

The challenge with rhythm control medications is selectivity. Heart cells throughout the body use similar ion channels, so drugs that calm the atria can also affect the ventricles, sometimes triggering different dangerous arrhythmias—a paradox where the treatment itself causes electrical chaos. This is why doctors carefully weigh each patient's specific situation, sometimes choosing to control rate rather than restore rhythm, accepting continued fibrillation as preferable to medication risks.